Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658892 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00658892: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00658892 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00658892, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a monoclonal antibody in treating patients with stage IV melanoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER flow cytometry
- OTHER immunologic technique
- BIOLOGICAL B7-DC cross-linking antibody rHIgM12B7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-04-08 |
| Est. Completion | 2012-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658892
The ClinicalTrials.gov registry entry for NCT00658892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00658892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658892 about?
NCT00658892 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a mon...
What is the current status of trial NCT00658892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-04-08. Estimated completion is 2012-05-22.
What interventions are being tested in trial NCT00658892?
The interventions under investigation include: laboratory biomarker analysis (OTHER), flow cytometry (OTHER), immunologic technique (OTHER), B7-DC cross-linking antibody rHIgM12B7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00658892?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.